Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nanoviricides Inc (NY: NNVC )

1.280 -0.050 (-3.76%)
Streaming Delayed Price Updated: 3:05 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 47,849
Open 1.330
Bid (Size) 1.270 (2)
Ask (Size) 1.280 (7)
Prev. Close 1.330
Today's Range 1.280 - 1.340
52wk Range 1.000 - 3.590
Shares Outstanding 14,347,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports Financial Progress and Advances Towards Key Phase II Clinical Trials
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
Via ACCESSWIRE

Performance

YTD
+24.27%
+24.27%
1 Month
-12.93%
-12.93%
3 Month
-36.95%
-36.95%
6 Month
-43.61%
-43.61%
1 Year
+17.43%
+17.43%

More News

Read More
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Broad-Spectrum Antiviral Advancements at Spartan Capital Investors Conference
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
Via ACCESSWIRE
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Present Breakthrough Antiviral Platform and Drug Delivery Advances at PODD Conference
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides President Dr. Diwan to Present at the PODD Conference
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) CEO Featured in Latest Episode of PODD Podcast
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
Via ACCESSWIRE
InvestorNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) to Discuss Its ‘Trojan Horse’ Platform Technology at Upcoming Global AMR Summit
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Announces Filing of Fiscal 2024 Form 10-K
Via Investor Brand Network
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
Via ACCESSWIRE
BioMedNewsBreaks — NanoViricides Inc. (NYSE American: NNVC) Announces Execution of MoU Agreement with TheraCour Pharma
Via Investor Brand Network
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
Via ACCESSWIRE
MPOX is Emerging as a Global Threat - NanoViricides Investigating MEURI Protocol for Using NV-387 to Treat MPOX
Via ACCESSWIRE
NanoViricides Continues Its March Towards a Phase II Clinical Trial of NV-387 -
A Potentially Revolutionary First Line Antiviral Therapy for RSV, COVID, and Other Viral Infections
Via ACCESSWIRE
NanoViricides Provides an Update on Its Clinical Program and Strategy - NV-387 Could be As Revolutionary as Antibiotics
Via ACCESSWIRE
Rapid Advancements of Innovative Antiviral – COVID-19 Drugs Generating Major Growth in Global Antiviral Drugs Market
Via FinancialNewsMedia
Exposures COVID-19
Can Nanotechnology offer Better Solutions for COVID, RSV and other Viruses?
Via Newsfile
Exposures COVID-19
"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides
Via ACCESSWIRE
COVID is Here to Stay and NV-387 is a Much Needed Drug Against It, Reminds NanoViricides
Via ACCESSWIRE
A Single Drug Against Multiple Respiratory Virus Infections - COVID, RSV, Influenza, Bird Flu - Planning Next Phase of Clinical Trials, Says NanoViricides
Via ACCESSWIRE
NanoViricides is Well Positioned with Its Clinical and Pre-Clinical Pipeline and Unique Host-Mimetic, Virus Killing, Technology Platform Intending To Revolutionize Treatment of Viral Infections
Via ACCESSWIRE
A Novel Broad-Spectrum Antiviral Against Influenza A Viruses, NV-387, Could Be an Important Weapon to Fight Bird Flu H5N1, Says NanoViricides
Via ACCESSWIRE
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.